News
XENT
28.24
0.00%
0.00
Webull provides a variety of real-time XENT stock news. You can receive the latest news about Intersect Ent through multiple platforms. This information may help you make smarter investment decisions.
About XENT
Intersect ENT, Inc. is an ear, nose and throat medical technology provider. Its products are steroid releasing implants designed to treat patients suffering from chronic rhinosinusitis. Its products include the PROPEL family of products PROPEL, PROPEL Mini and PROPEL Contour, and the SINUVA, mometasone furoate Sinus Implant. The PROPEL family of products are used in conjunction with sinus surgery primarily in hospitals and ambulatory surgery centers, as well as used in the physician office setting of care in conjunction with balloon dilation and various post-surgical debridement. SINUVA is a physician administered drug, designed to be used in the physician office setting of care to treat adult patients who have had ethmoid sinus surgery yet suffer from recurrent sinus obstruction due to polyps. It also offers ENT products, including the VENSURE sinus dilation platform and the CUBE surgical navigation system and instrumentation, which complements its PROPEL and SINUVA sinus implants.